Should I buy or sell ADMA Biologics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last twelve months. There are currently 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ADMA shares. View ADMA analyst ratings or view top-rated stocks .

What is ADMA Biologics' stock price target for 2024?

4 analysts have issued 12-month price objectives for ADMA Biologics' stock. Their ADMA share price targets range from $6.00 to $10.00. On average, they expect the company's stock price to reach $7.88 in the next year. This suggests a possible upside of 25.6% from the stock's current price. View analysts price targets for ADMA or view top-rated stocks among Wall Street analysts .

How have ADMA shares performed in 2024?

ADMA Biologics' stock was trading at $4.52 at the beginning of the year. Since then, ADMA stock has increased by 38.7% and is now trading at $6.27. View the best growth stocks for 2024 here .

Are investors shorting ADMA Biologics?

ADMA Biologics saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 7,290,000 shares, a decrease of 8.8% from the March 15th total of 7,990,000 shares. Based on an average daily volume of 2,750,000 shares, the short-interest ratio is currently 2.7 days. View ADMA Biologics' Short Interest .

When is ADMA Biologics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our ADMA earnings forecast .

How were ADMA Biologics' earnings last quarter?

ADMA Biologics, Inc. (NASDAQ:ADMA) announced its earnings results on Wednesday, February, 28th. The biotechnology company reported $0.04 EPS for the quarter, topping analysts' consensus estimates of $0.02 by $0.02. The biotechnology company had revenue of $73.90 million for the quarter, compared to analysts' expectations of $73.50 million. ADMA Biologics had a negative net margin of 10.94% and a positive trailing twelve-month return on equity of 0.49%.

What ETFs hold ADMA Biologics' stock?

ETFs with the largest weight of ADMA Biologics (NASDAQ:ADMA) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP) , Invesco Dorsey Wright Healthcare Momentum ETF (PTH) and Invesco DWA SmallCap Momentum ETF (DWAS) . iShares Micro-Cap ETF (IWC) .

What guidance has ADMA Biologics issued on next quarter's earnings?

ADMA Biologics updated its FY 2025 earnings guidance on Wednesday, February, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $380.0 million-.

What is Adam S. Grossman's approval rating as ADMA Biologics' CEO?

9 employees have rated ADMA Biologics Chief Executive Officer Adam S. Grossman on Glassdoor.com . Adam S. Grossman has an approval rating of 29% among the company's employees. This puts Adam S. Grossman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ADMA Biologics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ADMA Biologics investors own include Matinas BioPharma (MTNB) , Pennsylvania Real Estate Investment Trust (PEI) , Organigram (OGI) , Gran Tierra Energy (GTE) , Tilly's (TLYS) , Bionano Genomics (BNGO) , Novan (NOVN) , CNBX Pharmaceuticals (CNBX) , Zosano Pharma (ZSAN) and DHT (DHT) .

Who are ADMA Biologics' major shareholders?

ADMA Biologics' stock is owned by many different institutional and retail investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.11%), First Hawaiian Bank (0.05%), EWG Elevate Inc. (0.04%), Mesirow Financial Investment Management Inc. (0.03%), Prism Advisors Inc. (0.01%) and Viewpoint Capital Management LLC (0.01%). Insiders that own company stock include Adam S Grossman , Brian Lenz , Bryant Fong, Jerrold B Grossman, Perceptive Advisors Llc, Steve Elms and Young Kwon . View institutional ownership trends .

How do I buy shares of ADMA Biologics?

Shares of ADMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ADMA

ADMA Biologics (ADMA) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free ADMA Stock Alerts

$6.27

+0.07 (+1.13%)

(As of 04/19/2024 ET)

Compare

Today's Range: $6.10
▼
$6.29
50-Day Range: $5.15
▼
$6.74
52-Week Range: $3.06
▼
$6.76

Volume: 3.41 million shs
Average Volume: 2.66 million shs
Market Capitalization: $1.43 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.88

Get ADMA Biologics alerts:

ADMA Biologics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.25 Rating Score
Upside/Downside: 25.6% Upside
$7.88 Price Target
Short Interest: Healthy
3.19% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.00
Based on 5 Articles This Week
Insider Trading: Selling Shares
$3.93 M Sold Last Quarter
Proj. Earnings Growth: 66.67%
From $0.30 to $0.50 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.92 out of 5 stars

Medical Sector

185th out of 911 stocks

Biological Products, Except Diagnostic Industry

17th out of 148 stocks

3.6

Analyst's Opinion

Consensus Rating
ADMA Biologics has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
ADMA Biologics has only been the subject of 3 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
3.19% of the outstanding shares of ADMA Biologics have been sold short.
Short Interest Ratio / Days to Cover
ADMA Biologics has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in ADMA Biologics has recently decreased by 8.76%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
ADMA Biologics does not currently pay a dividend.
Dividend Growth
ADMA Biologics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ADMA.

2.8

News and Social Media Coverage

News Sentiment
ADMA Biologics has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for ADMA Biologics this week, compared to 3 articles on an average week.
Search Interest
Only 24 people have searched for ADMA on MarketBeat in the last 30 days. This is a decrease of -48% compared to the previous 30 days.
MarketBeat Follows
Only 15 people have added ADMA Biologics to their MarketBeat watchlist in the last 30 days. This is a decrease of -44% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ADMA Biologics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,927,169.00 in company stock.
Percentage Held by Insiders
Only 6.00% of the stock of ADMA Biologics is held by insiders.
Percentage Held by Institutions
75.68% of the stock of ADMA Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for ADMA Biologics are expected to grow by 66.67% in the coming year, from $0.30 to $0.50 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ADMA Biologics is -48.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ADMA Biologics is -48.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ADMA Biologics has a P/B Ratio of 10.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About ADMA Biologics Stock (NASDAQ:ADMA)

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

ADMA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ADMA Stock News Headlines

March 20, 2024 | insidertrades.com

Insider Selling: ADMA Biologics, Inc. (NASDAQ:ADMA) Director Sells 49,887 Shares of Stock

April 17, 2024 | americanbankingnews.com

ADMA Biologics, Inc. (NASDAQ:ADMA) Short Interest Down 8.8% in March

April 20, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 16, 2024 | morningstar.com

ADMA Biologics Inc

April 3, 2024 | seekingalpha.com

Rising Margins And Product Promise Drive ADMA Biologics Forward (Rating Upgrade)

April 1, 2024 | finance.yahoo.com

Investors in ADMA Biologics (NASDAQ:ADMA) have seen splendid returns of 261% over the past three years

March 27, 2024 | markets.businessinsider.com

ADMA Biologics Poised for Robust Growth: Buy Rating Affirmed with Enhanced Price Target

March 26, 2024 | markets.businessinsider.com

A Closer Look at 6 Analyst Recommendations For ADMA Biologics

April 20, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 17, 2024 | investing.com

Adma Biologics director Steve Elms sells over $6.3 million in company stock

March 16, 2024 | finance.yahoo.com

ADMA Apr 2024 5.000 put

March 15, 2024 | finance.yahoo.com

Adma Biologics (ADMA) Stock Moves -0.5%: What You Should Know

March 11, 2024 | finanznachrichten.de

ADMA Biologics, Inc.: ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV & BIVIGAM

March 11, 2024 | globenewswire.com

ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV™ & BIVIGAM®

March 5, 2024 | globenewswire.com

ADMA Biologics to Participate in the Raymond James Institutional Investor Conference

March 1, 2024 | seekingalpha.com

ADMA Biologics, Inc. (ADMA) Q4 2023 Earnings Call Transcript

March 1, 2024 | finance.yahoo.com

ADMA Biologics Full Year 2023 Earnings: EPS Misses Expectations

February 29, 2024 | uk.finance.yahoo.com

Q4 2023 ADMA Biologics Inc Earnings Call

February 29, 2024 | finanznachrichten.de

ADMA Biologics, Inc.: ADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

February 29, 2024 | finanznachrichten.de

ADMA Biologics, Inc.: ADMA Biologics Announces CFO Transition

February 29, 2024 | finance.yahoo.com

ADMA Biologics, Inc. (NASDAQ:ADMA) Q4 2023 Earnings Call Transcript

February 29, 2024 | markets.businessinsider.com

Forecasting The Future: 4 Analyst Projections For ADMA Biologics

February 28, 2024 | msn.com

ADMA Biologics GAAP EPS of -$0.08 misses by $0.11, revenue of $73.9M beats by $0.93M

February 28, 2024 | msn.com

ADMA Biologics' CFO to step down

February 28, 2024 | marketwatch.com

ADMA Biologics Says CFO Brian Lenz Moving to Consulting Role

February 28, 2024 | finance.yahoo.com

ADMA Biologics Inc Reports Robust Revenue Growth and Positive Adjusted Net Income for FY 2023

February 28, 2024 | globenewswire.com

ADMA Biologics Announces CFO Transition

See More Headlines

Receive ADMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMA Biologics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:ADMA
CUSIP: N/A
CIK: 1368514
Web: www.admabiologics.com
Phone: (201) 478-5552
Fax: 201-478-5553
Employees: 624
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $7.88
High Stock Price Target: $10.00
Low Stock Price Target: $6.00
Potential Upside/Downside: +25.6%
Consensus Rating: Buy
Rating Score (0-4): 3.25
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.13)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 20.90
P/E Growth: N/A
Net Income: $-28,240,000.00
Net Margins: -10.94%
Pretax Margin: -10.94%
Return on Equity: 0.49%
Return on Assets: 0.21%

Debt

Debt-to-Equity Ratio: 1.04
Current Ratio: 5.16
Quick Ratio: 1.69

Sales & Book Value

Annual Sales: $258.22 million
Price / Sales: 5.54
Cash Flow: $0.05 per share
Price / Cash Flow: 118.86
Book Value: $0.60 per share
Price / Book: 10.45

Miscellaneous

Outstanding Shares: 228,220,000
Free Float: 214,527,000
Market Cap: $1.43 billion
Optionable: Optionable
Beta: 0.46

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

Mr. Adam S. Grossman (Age 47)
Co-Founder, President, CEO & Director
Comp: $1.52M
Dr. Jerrold B. Grossman D.P.S. (Age 76)
Ph.D., Co-Founder & Vice Chairman of the Board
Comp: $80k
Mr. Brian Lenz CPA (Age 52)
Executive VP, CFO & GM of ADMA BioCenters
Comp: $1.08M
Ms. Kaitlin Kestenberg (Age 37)
COO & Senior VP of Compliance
Mr. Drew Pantello
Vice President of Marketing & Corporate Development
Ms. Cindy Petersen
Executive Director of Human Resources
Mr. Skyler Bloom
Senior Director of Business Development & Corporate Strategy

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ADMA Stock Analysis - Frequently Asked Questions

Should I buy or sell ADMA Biologics stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last twelve months. There are currently 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ADMA shares.
View ADMA analyst ratings or view top-rated stocks.
What is ADMA Biologics' stock price target for 2024?: 4 analysts have issued 12-month price objectives for ADMA Biologics' stock. Their ADMA share price targets range from $6.00 to $10.00. On average, they expect the company's stock price to reach $7.88 in the next year. This suggests a possible upside of 25.6% from the stock's current price.
View analysts price targets for ADMA or view top-rated stocks among Wall Street analysts.
How have ADMA shares performed in 2024?: ADMA Biologics' stock was trading at $4.52 at the beginning of the year. Since then, ADMA stock has increased by 38.7% and is now trading at $6.27.
View the best growth stocks for 2024 here.
Are investors shorting ADMA Biologics?: ADMA Biologics saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 7,290,000 shares, a decrease of 8.8% from the March 15th total of 7,990,000 shares. Based on an average daily volume of 2,750,000 shares, the short-interest ratio is currently 2.7 days.
View ADMA Biologics' Short Interest.
When is ADMA Biologics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our ADMA earnings forecast.
How were ADMA Biologics' earnings last quarter?: ADMA Biologics, Inc. (NASDAQ:ADMA) announced its earnings results on Wednesday, February, 28th. The biotechnology company reported $0.04 EPS for the quarter, topping analysts' consensus estimates of $0.02 by $0.02. The biotechnology company had revenue of $73.90 million for the quarter, compared to analysts' expectations of $73.50 million. ADMA Biologics had a negative net margin of 10.94% and a positive trailing twelve-month return on equity of 0.49%.

What ETFs hold ADMA Biologics' stock?: ETFs with the largest weight of ADMA Biologics (NASDAQ:ADMA) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), Invesco Dorsey Wright Healthcare Momentum ETF (PTH) and Invesco DWA SmallCap Momentum ETF (DWAS).iShares Micro-Cap ETF (IWC).
What guidance has ADMA Biologics issued on next quarter's earnings?: ADMA Biologics updated its FY 2025 earnings guidance on Wednesday, February, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $380.0 million-.
What is Adam S. Grossman's approval rating as ADMA Biologics' CEO?: 9 employees have rated ADMA Biologics Chief Executive Officer Adam S. Grossman on Glassdoor.com. Adam S. Grossman has an approval rating of 29% among the company's employees. This puts Adam S. Grossman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of ADMA Biologics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ADMA Biologics investors own include Matinas BioPharma (MTNB), Pennsylvania Real Estate Investment Trust (PEI), Organigram (OGI), Gran Tierra Energy (GTE), Tilly's (TLYS), Bionano Genomics (BNGO), Novan (NOVN), CNBX Pharmaceuticals (CNBX), Zosano Pharma (ZSAN) and DHT (DHT).
Who are ADMA Biologics' major shareholders?: ADMA Biologics' stock is owned by many different institutional and retail investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.11%), First Hawaiian Bank (0.05%), EWG Elevate Inc. (0.04%), Mesirow Financial Investment Management Inc. (0.03%), Prism Advisors Inc. (0.01%) and Viewpoint Capital Management LLC (0.01%). Insiders that own company stock include Adam S Grossman, Brian Lenz, Bryant Fong, Jerrold B Grossman, Perceptive Advisors Llc, Steve Elms and Young Kwon.
View institutional ownership trends.
How do I buy shares of ADMA Biologics?: Shares of ADMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ADMA) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

ADMA Biologics (ADMA) Stock Price, News & Analysis

ADMA Biologics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About ADMA Biologics Stock (NASDAQ:ADMA)

ADMA Stock Price History

ADMA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ADMA Stock Analysis - Frequently Asked Questions

Overall MarketRank^™